Next Article in Journal
Environmental Amoxicillin Exposure Induces Cardiotoxicity in Zebrafish Embryos: A Comprehensive Assessment of Heart Function and Molecular Responses
Previous Article in Journal
Looking for ESKAPE Bacteria: Occurrence and Phenotypic Antimicrobial Resistance Profiles in Wild Birds from Northern and Central Italy Sites
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Antibiotics
Volume 14
Issue 10
10.3390/antibiotics14101026
antibiotics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Peri-Operative Antimicrobial Prophylaxis Modulates CD4+ Lymphocyte Immunophenotype Ex Vivo in High-Risk Patients Undergoing Major Elective Surgery—A Preliminary Observational Study

by
Susi Paketci
1,†,
Jack Williams
1,†,
Walter Pisciotta
1,
Richard Loye
1,
Alessia V. Waller
1,
Rahila Haque
1,
David Brealey
1,2,
Mervyn Singer
1,
John Whittle
3,
Ramani Moonesinghe
2,3,
Nishkantha Arulkumaran
1,‡,
Timothy Arthur Chandos Snow
1,3,*,‡ and
the University College London Hospitals Critical Care Research Team
§
1
Bloomsbury Institute of Intensive Care Medicine, University College London, London WC1E 6BT, UK
2
NIHR UCLH Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London NW1 2BU, UK
3
Centre for Anaesthesia, Critical Care & Pain Medicine, University College London, London WC1E 6BT, UK
*
Author to whom correspondence should be addressed.
†
Joint First author.
‡
Joint Senior author.
§
University College London Hospitals Critical Care Research Team: Naveed Saleem, Antonio Cesar, Francis Ryckaert, Deborah Smyth, Georgia Bercades, Ingrid Hass, Alexandra Zapata Martinez, Laura Gallagher, and Gladys Martir.
Antibiotics 2025, 14(10), 1026; https://doi.org/10.3390/antibiotics14101026
Submission received: 29 August 2025 / Revised: 8 October 2025 / Accepted: 10 October 2025 / Published: 14 October 2025
(This article belongs to the Special Issue Antimicrobial Stewardship in Surgical Infection)
Browse Figures
Review Reports Versions Notes

Abstract

Background: Post-operative infections are a significant cause of morbidity in patients undergoing major elective surgery. Peri-operative antibiotics are used to reduce the risk of infection. Several antibiotics modulate the host immune response. Objectives: Our objective was to determine the ex vivo immunomodulatory properties of commonly used antibiotics (amoxicillin, cefuroxime, metronidazole, or combined cefuroxime–metronidazole) on monocyte and lymphocyte phenotypes in patients undergoing major elective surgery. Methods: We performed a prospective cohort study of patients aged ≥18 years admitted to the post-anaesthetic care unit following major elective non-cardiac surgery. Peripheral blood mononuclear cells isolated immediately after surgery were incubated with antibiotics with or without a monocyte (heat-killed E. coli) or lymphocyte (CD3/CD28 beads) stimulus ex vivo. Immune cell phenotype was characterised using flow cytometry. Results: Twenty-eight patients were included. All antibiotics tested were associated with a reduction in T-cell viability, and changes to monocytes were minimal. Among CD4+ and CD8+ lymphocytes, cefuroxime increased IFN-γ (at low and high doses) and increased CD4+ lymphocyte IL-2 and IL-2R at higher doses. Among CD4+ lymphocytes, at both doses, cefuroxime increased %Th1 population, with a parallel decrease in %Th2, %Th17, IL-17A, FOX-P3, and T-bet. Among the Th1 sub-population, changes were seen at higher cefuroxime doses, including increased viability and PD-1, and a decrease in FAS, IFN-γ and CD28, and IL-7R expression. Conclusions: The choice of antibiotics directly impacts immune function following major surgery, with cefuroxime associated with ex vivo immunomodulatory effects on CD4+ lymphocytes. The functional implications on the development of subsequent post-operative infectious complications and long-term cancer-free survival require further investigation.

1. Introduction

Post-operative infections (encompassing pneumonia, surgical-site infections, etc.) are a significant cause of morbidity. The reported incidence varies between studies, depending on the definition and reporting of infections, the patient cohort, and type of surgery; ranging from 9% in a global survey of all surgical specialities [1], to 40% of patients undergoing major non-cardiac surgery at tertiary referral specialist centres [2]. Surgery activates the immune system in response to physical injury to tissues (‘sterile inflammation’), which shares many similarities with the immune changes seen in sepsis [3]. An immunophenotype consistent with immunosuppression is commonplace in patients who develop post-operative infections and those with sepsis who develop secondary infections [4,5]. Several of the immune responses following surgery, such as a reduction in monocyte HLA-DR and persistent lymphopenia, are associated with development of subsequent infections [6,7,8] and are similar to the changes seen in patients who die with subsequent infections following sepsis [9].
The conventional approach to reducing the risk of post-operative infections is the liberal use of antibiotics [10]. However, there has been considerable effort to reduce the excessive use of antibiotics due to the increasing prevalence of antimicrobial resistance; guidelines recommend only administrating in cases of clean surgery with prosthesis insertion, or if surgical contamination occurs [11]. Beta-lactams (penicillins and cephalosporins) and nitroimidazoles are the most frequently used classes in a recent meta-analysis of antimicrobial prophylaxis regimens [12] (Supplemental Table S1), with amoxicillin, cefuroxime, and metronidazole currently recommended by UK guidelines [13]. Cefuroxime and metronidazole may be better in preventing post-operative infections compared to other antibiotics, related to their effect on different antimicrobial spectra [14].
In addition to concerns regarding antimicrobial resistance, understanding and awareness of antibiotic side-effects are increasing. Pre-clinical data demonstrates inadvertent effects of antibiotics on the immune system [15]. However, it is unclear if this affects patient outcomes, including the risk of late infections [16].
Our primary objective was to evaluate the ex vivo effect of amoxicillin, cefuroxime, metronidazole, and combined cefuroxime–metronidazole on immune cell phenotype in patients undergoing major surgery.

2. Results

2.1. Study Participants

Twenty-eight patients were included in this study (antibiotic characterisation cohort). An initial analysis of changes to immune cell phenotype was conducted in 12 patients (immunophenotyping cohort). Based on these data, a focused and in-depth characterisation of immune cell phenotype was conducted in another 16 patients (lymphocyte characterisation cohort). Patients had a median age of 64 (54–75) and 54% were male. 16/28 (57%) underwent upper gastrointestinal, 5/28 (18%) maxillofacial, 5/28 (18%) gynaecological, and 2/28 (7%) lower GI surgery. Most patients 27/28 (96%) underwent surgery for cancer resection, of whom 17/28 (61%) had received neoadjuvant chemotherapy. All patients received peri-operative antimicrobial prophylaxis; 17/28 (61%) received cefuroxime and metronidazole, 5/28 (18%) received co-amoxiclav, and 2/28 (7%) ciprofloxacin and clindamycin. Median duration of prophylactic antibiotic administration was 1(1–1) day. (Table 1 and Supplemental Figure S1).

2.2. Effects of Antibiotics on Post-Operative PBMCs in the Immunophenotyping Cohort

In CD4+ and CD8+ lymphocytes, high-dose amoxicillin increased IFN-γ concentration. (Supplemental Figure S2(a.iv.,a.vi.)) Additionally, in CD8+ lymphocytes, high-dose amoxicillin increased CD28 expression (Supplemental Figure S2(a.vi.)) with decreased CTLA-4 expression (Supplemental Figure S2(a.vi.)) and cell viability (Supplemental Figure S2(a.vi.)). CD4+ and CD8+ lymphocyte viability was reduced by metronidazole at low (Supplemental Figure S2(c.iii.)) and high doses (Supplemental Figure S2(c.iv.,v.i.)). Amoxicillin and metronidazole had no effect on monocyte phenotype. (Supplemental Figure S2(a.i.,a.ii.,c.i.,c.ii.)).
In CD4+ and CD8+ lymphocytes, cefuroxime increased IFN-γ concentration (Figure 1(a.i.,a.ii.,c.ii.,c.iii.), and Supplemental Figure S3(a.iii.)) and decreased viability (Figure 1(a.i.,a.ii.,c.i.), and Supplemental Figure S3(a.iv.)) at both doses. There were additional effects at a high dose, including an increase in CD4+ lymphocyte IL-2 concentration (Figure 1(b.i.,b.iii.), and Supplemental Figure S3(a.i.)) and IL-2R (Figure 1(b.ii.,b.iii.), and Supplemental Figure S3(a.ii.)), and decreased CD8 lymphocyte CTLA-4 (Supplemental Figure S4(a.vi.)) and increased IL-2R expression (Supplemental Figure S4(a.vi.)). Cefuroxime had no effect on monocyte phenotype. (Supplemental Figure S4(a.i.,a.ii.)).
Cefuroxime is often co-administered with metronidazole. When combined with metronidazole, the immunomodulatory effects were similar to that of cefuroxime alone. (Supplemental Figure S4c) This data suggested cefuroxime may have an immunomodulatory role on lymphocyte function and/or differentiation. We therefore proceeded to evaluate detailed T-cell subset phenotype changes induced by cefuroxime.

2.3. Cefuroxime Promotes CD4+ Lymphocyte Differentiation Towards a Th1 Phenotype in the Lymphocyte Characterisation Cohort

IL-17A was suppressed at both doses in CD4+ and CD8+ lymphocytes. (Figure 2(a.i.,a.ii.), Supplemental Figure S3(b.v.), and Supplemental Figure S5(a.i.,a.ii.,b.i.,b.ii.). CCR4, T-bet and Fox-P3 were reduced in CD4+ lymphocytes. (Figure 2(a.i.,a.ii.,b.ii.), Supplemental Figure S3(b.vi.,c.i.,c.iv.), and Supplemental Figure S5(a.i,a.ii)). Among CD4+ and CD8+ lymphocytes, proportions of Th1 (Figure 2(b.i.,b.ii.), Supplemental Figure S3(b.i.), and Supplemental Figure S5(a.i,a.ii)) and Tc1 cell populations (Figure S5(b.i,b.ii)) increased with a parallel decrease in Th2, Th17, and Tc17 cell populations at both low and high dose cefuroxime (Figure 2(a.i.,a.ii.), Supplemental Figure S3(b.ii.,b.iii.), and Supplemental Figure S5(a.i.,a.ii.,b.i.,b.ii.)). As cefuroxime increased the proportion of Th1 subsets and CD4+ lymphocyte IFN-γ, we further characterised cefuroxime-related changes to Th1 lymphocytes.

2.4. Cefuroxime Has an Immunomodulatory Effect on Th1 Subset Function in the Lymphocyte Characterisation Cohort

At a high dose, cefuroxime was associated with reduced activation of Th1 lymphocytes with reduced CD28, IFN-γ, and Fas, and a trend towards increased expression of PD-1 and reduced expression of IL-7R, although changes did not reach statistical significance. (Figure 3(a.ii.,b.i.,b.ii.,b.iii.), Supplemental Figure S3(d.i.,d.iii.–vi.), and Supplemental Figure S6ii.) This reduced activation-associated cell death as viability was increased (Figure 3(b.iii.) and Supplemental Figure S3(d.ii.)). No immunomodulatory effect was seen with low dose cefuroxime. (Figure 3(a.i.) and Supplemental Figure S6i.).
Cefuroxime was associated with lower levels of supernatant IL-10 at 72 h in unstimulated cells, with no differences at earlier timepoints. (Supplemental Figure S7b) There were no differences in IFN-γ at any time point. (Supplemental Figure S7a).

2.5. Effect of Stimulus on Post-Operative Immune Cell Phenotype in the Immunophenotyping Cohort

Following 24 h incubation with heat-killed E. coli, there was an increase in intracellular cytokine expression (IL-1β and IL-6), a decrease in chemokine receptor expression (CXCR4), cell viability, and population percentage. Markers associated with antigen presentation demonstrated an immunosuppressive phenotype (increased CD80, decreased CD86, and a trend towards suppressed HLA-DR). (Supplemental Figure S8i.).
After 72 h incubation with CD3-28 beads, CD4+ lymphocytes demonstrated an increase in cytokine expression (IFN-γ) and markers of differentiation (IL-2 expression), with a decrease in co-stimulatory receptor (CD28) and proliferation (IL-7R). (Supplemental Figure S8ii.) CD8+ lymphocytes showed an increase in cytokine expression (IFN-γ and IL-10) and markers of differentiation (IL-2 expression), with a decrease in co-stimulatory receptor (CD28) proliferation (IL-7R) and anergy (PD-1). (Supplemental Figure S8iii.).

2.6. Effects of Antibiotics on Stimulated Post-Operative Cells in the Immunophenotyping Cohort

Amoxicillin had no effect on stimulated monocytes or lymphocytes. (Supplemental Figure S2b). Metronidazole also had no effect on stimulated monocyte phenotype. (Supplemental Figure S2(d.i.,d.ii.)). In stimulated CD8+ lymphocytes, metronidazole decreased cell viability at a low dose (and high dose in univariate analysis), with no changes in CD4+ phenotype. (Supplemental Figure S2(d.iii–vi.)).
Cefuroxime had no effect on stimulated monocyte immunophenotype, (Supplemental Figure S4(b.i,b.ii.)) but in stimulated CD4+ and CD8+ lymphocytes, cefuroxime increased IFN-γ concentration and decreased viability at a high dose only. (Supplemental Figure S4(b.iv.,b.vi.)) In stimulated lymphocytes, no additional effects were seen on lymphocyte differentiation (Supplemental Figure S5(a.iv.,a.v.)) or on Th1 subset function. (Supplemental Figure S6(iv.,v.)).
Combined cefuroxime–metronidazole had no effect on stimulated monocytes, but in stimulated CD4+ and CD8+ lymphocytes, it caused a decrease in viability and an increase in IFN-γ concentration at a high dose only. (Supplemental Figure S4(d.vi.)).
There were no differences in either released IL-10 or IFN-γ in stimulated PBMCs. (Supplemental Figure S7).

2.7. Post-Operative Infections

We assessed whether the ex vivo effects of cefuroxime were associated with differences in the incidence of post-operative infections. Analysis was performed on our previously published clinical cohort, which from which the current dataset was derived [8], including 83 patients, 42 (51%) of whom were diagnosed with a post-operative infection, and occurring on day 3 (2–4). Patients either received cefuroxime (n = 53, alone or combined with other antibiotics), or any other antibiotic (n = 30, alone or in combination).
The other antibiotic cohort represented patients undergoing maxillofacial and gynaecological surgery, with a higher proportion of female patients in this group (67% vs. 32%), and fewer patients had received neo-adjuvant chemotherapy (33% vs. 62%) (Supplemental Table S2 and Supplemental Figure S9). Among patients receiving cefuroxime, 27 patients (51%) developed an infection, compared to 15 patients (50%) receiving other antibiotics (p = 0.831).

3. Discussion

Surgery induces several changes to the immune system [17,18,19]. We have previously described specific changes associated with post-operative infections including the following: elevated monocyte cell count, reduced monocyte chemokine receptor expression (CXCR4), and an increase in CD4+ lymphocyte IL-7R expression [8]. Here, we provide ex vivo evidence that the choice of antimicrobial prophylaxis may influence these changes.
In summary, we found that all antibiotics tested were associated with a reduction in lymphocyte viability, and changes to monocytes were minimal. Among CD4+ and CD8+ lymphocytes, cefuroxime increased IFN-γ and reduced viability (at low and high doses) and increased IL-2 and IL-2R at higher doses. Among CD4+ lymphocytes, at both doses, cefuroxime increased %Th1 population and decreased %Th2, %Th17, IL-17A, FOX-P3, and T-bet expression. Among the Th1 population, changes were only seen at higher cefuroxime doses, including increased viability and PD-1 and a decrease in FAS, IFN-γ and CD28, and IL-7R.
These findings all form part of the Th1 lymphocyte subset response, strongly suggesting that the immunomodulatory mechanism of action of cefuroxime is on this specific lymphocyte subset.
Lymphocytes are integral to the adaptive immune response. In response to the surgical insult, they activate, proliferate, and differentiate into subsets each with specific functions. Following resolution of inflammation, they undergo a natural process of apoptosis, leaving memory cells which are capable of reactivating upon repeated exposure to the same stimulus. Too few of these cells, lymphopenia, and impairments in function of the remaining cells, anergy, are associated with an increased risk of developing post-operative infections [8,20,21]. Maintaining both the number and function of lymphocytes in the immediate post-operative period could reduce the incidence of post-operative infections.
CD4+ lymphocytes are responsible for the elimination of intra- and extracellular pathogens, and clearance of tumours which evade cytotoxic CD8+ lymphocytes [22,23] and are therefore critical in the immediate post-operative period to prevent both infections and tumour recurrence in cancer surgery. IL-2 and its receptor are important in the proliferation and differentiation of CD4+ lymphocytes, specifically of naïve to helper T-cell subtypes following infection [24]. Additionally, IL-2 promotes proinflammatory cytokine release from helper T-cells aiding the initial immune response. However, prolonged release induces an immunosuppressive phenotype by inhibiting cytokine release in Th17 cells, a subset especially important in bacterial clearance, and has additional immunoregulatory and suppressive effects on the Treg subset, which have broadly immunosuppressive effects important in the resolution of inflammation. Post-operatively, IL-2 concentration and IL-2R expression decrease, with a nadir around days 3–4 post-operatively, which corresponds with the timing of the development of post-operative infections in our cohort [25,26,27]. Whilst this suggests that reduced IL-2 and its receptor may be preventing CD4+ proliferation and differentiation, therefore increasing the risk of post-operative infections, administration of therapeutic IL-2 following surgery [28] did not prevent the initial lymphopenia. Strategies which ameliorate acute reductions in IL-2 cytokine concentration and receptor expression, however, may be beneficial.
We demonstrate that cefuroxime was able to increase both intracellular IL-2 and surface IL-2R expression. Cephalosporins, including cefuroxime, have previously been shown to have immunomodulatory effects on CD4+ lymphocyte proliferation, although at high doses they may cause downregulation of IL-2R gene expression and inhibition of proliferation [29,30,31,32,33]. This effect has not been reliably reproduced with beta-lactams, despite the relative cross-reactivity between the two classes [33] suggesting this may be a cephalosporin-only effect.
Whilst this suggests that using cefuroxime as prophylaxis could have beneficial effects, excessive IL-2R activation is also associated with increased cell death through IL-2 activation-induced cell death. Several mechanisms are implicated, including the Fas receptor, mitochondrial, and caspase-3 mediated cell death pathways [34,35]. Beta-lactams induce cell death via direct damage to cellular DNA and through mitochondrial pathways [36,37]. Whilst the assessed antibiotics reduced overall cell viability, cefuroxime was associated with increased viability and a reduction in Fas expression in the Th1 subset, suggesting a potential protective effect in this subset. Th1 lymphocytes are important in the immune response against intracellular pathogens and activate antigen-presenting cells, including monocytes. However, it should be noted that there was an increase in PD-1, a receptor also implicated in T-cell anergy. Cephalosporins upregulate Th1 cell PD-1 expression in a mouse model of pneumonia; however, the association of antibiotics with this receptor and eventual cell death remains unexplored [38]. This suggests that the potential beneficial effects of using cephalosporins on normalisation of IL-2 and IL-2R may be countered by their effects on enhancing other immunosuppressive pathways. The balance of immunostimulatory and immunosuppressive effects in vivo, therefore, warrants further investigation.
We show that cefuroxime modulates the Th1/Th2 balance by enhancing the proportion of the Th1 subset, whilst reducing proportions of the Th2, Th17, and Treg subsets. Our findings are similar to previous data demonstrating that cephalosporins (ceftriaxone rather than cefuroxime) reduce the proportion of Tregs in a mouse model [39], whilst cefuroxime has previously been shown to downregulate genes associated with Th2 and Treg subset differentiation in PBMCs [33]. This was not a beta-lactam class effect, as ampicillin increased expression of these genes, suggesting a cephalosporin-specific effect. This is reinforced by the lack of effect of amoxicillin on markers associated with differentiation in our study, although we did not perform in-depth characterisation with amoxicillin or metronidazole. Whilst Th1 cells are important in the immune response to clear intracellular pathogens, both Th2 and Th17 cells aid in extracellular pathogen clearance, the latter especially at mucosal and epithelial barriers, which are often breached during surgery, and are therefore important in preventing surgical site infections. The clinical benefit of increasing the Th1 lymphocyte subpopulation whilst reducing the others is unknown.
In sepsis, Tregs have an immunosuppressive role [40], although their role in the peri-operative immune response is less clear. An increase in the proportion of this subset occurs following surgery [41]. This is associated with an increased risk of tumour recurrence [42,43], but not with the development of infectious complications [44]. Conversely, low pre-operative Tregs levels have been associated with the risk of developing cardiovascular complications in the post-operative period in patients undergoing non-cardiac surgery, although post-operative counts were not predictive [45]. It is therefore unclear whether the reduction in the Treg subset proportion induced by cefuroxime has any clinically relevant effect on peri-operative complications.
IFN-γ produced by CD4+ lymphocytes has important roles in tissue homeostasis, immune and inflammatory responses, and tumour immunosurveillance [46]. It acts on innate immune cells including macrophages, enhancing proinflammatory functions, and has local paracrine effects on other CD4+ lymphocytes, promoting Th1 function but suppressing Th17 response. Preliminary clinical studies of peri-operative IFN-γ administration have shown features consistent with an improvement in immune cell function, including increased monocyte HLA-DR expression and enhanced Th1 reactivity to specific antigens, but have yet to show clinical benefit [47,48]. We demonstrated that cefuroxime caused an increase in intracellular IFN-γ concentration, and this drives differentiation into Th1 cells. However it should be noted that high cefuroxime doses may impair IFN-γ release [49]. This may explain why IFN-γ concentration was reduced specifically in the Th1 subset and why the percentage of the Th17 subset was reduced at higher cefuroxime concentrations. Despite changes in intracellular IFN-γ concentration, we observed no differences in released cytokines, therefore the clinical effect of increased IFN-γ on enhancing the immune response may be limited, although cytokine release was measured from total PBMCs, rather than in isolated lymphocyte subsets.
Different classes of beta-lactams have heterogenous effects on the immune system [33,50]. This is reflected by the difference in allergy profiles to the different beta-lactams, which is likely due to the presence of only some cross-reactivity between amoxicillin and cephalosporins [51]. Therefore, immunomodulatory effects may be limited to specific antibiotic classes’ potentially supporting their preferential use over others.
Despite the potential beneficial immunomodulatory effects of cefuroxime demonstrated ex vivo, a clinical effect was not demonstrated in our cohort. This could be due to our limited sample size; the immune response to surgery is itself a large driver of immunophenotypical changes and therefore could mask the comparatively smaller additional effect of antibiotics. Additionally, alterations to lymphocyte phenotype induced by antibiotics may not alter the risk of post-operative complications following surgery [44]. Our results should be regarded as exploratory, warranting further investigation.
We chose to assess the immune response in the immediate post-operative period; results from patients pre-operatively and at later stages in their recovery may have yielded different findings. Our results are confounded by the high prevalence of active cancer and neoadjuvant chemotherapy in our cohort, and use of intra-operative dexamethasone [52]. Additionally, our patients all received peri-operative antibiotics prior to blood sampling for our in vitro analysis. All in vitro experiments were performed using a single concentration and strain of HKB or CD3/CD28 beads; a different immunological effect may have been seen with other concentrations or stimuli. However, as immune cells are stimulated by the immediate surgical response, the additional effect of another stimulus was minimal. Additional effects of antibiotics on stimulated cell functions may have become apparent at later time points during the patient recovery period, but as antibiotics were not administered beyond the immediate peri-operative period, the clinical relevance would be reduced. Experiments were performed on PBMCs rather than isolated cell populations, resulting in cell signalling between different cell subsets. We were also unable to account for differences in antimicrobial cover provided by the different antibiotics [14]. Our findings cannot be extrapolated to different patient populations and clinical practice.

4. Materials and Methods

4.1. Ethics

Ethical approval for obtaining clinical samples and data was received from the London—Queen Square Research Ethics Committee (REC reference 20/LO/1024) on 20 October 2020. Informed consent was obtained from all subjects involved in the study.

4.2. Clinical Study Participants

We conducted a prospective observational study of patients aged ≥ 18 years who were undergoing major elective surgery at University College London (UCL) Hospitals between 1 August 2021 and 31 July 2022. This was a sub-study of a previously published study investigating the early changes to immunophenotype on subsequent infections in high-risk patients undergoing non-cardiac major surgery [8]. In this study, preliminary analysis of changes to immune cell phenotype on exposure to antibiotics ex vivo was conducted in a cohort of 12 patients followed by an in-depth characterisation of immune cell phenotype in a cohort of 16 patients.
Major surgery was defined as a requirement for planned admission to the post-anaesthetic care unit (PACU) [53]. Routinely collected patient data, including demographics, clinical data (physiology, diagnoses), laboratory data, and clinical outcomes, were obtained from electronic healthcare records. The post-operative mortality risk was calculated using the surgical outcome risk tool (SORT) score [54], and the presence of a post-operative infection defined by the standardised endpoints in peri-operative medicine—core outcome measures for peri-operative and anaesthetic care (StEP-COMPAC) criteria [55]. Patients were followed up to hospital discharge or death.

4.3. Sample Processing

Patients were recruited prior to surgery. On arrival to the PACU, venesection was performed and 8 mls of blood drawn into a cell preparation tube with sodium heparin (CPTTM) vacutainer and a further 5 mL drawn into a serum tube (Beckton Dickinson, Wokingham, UK). Samples were processed within 1 h of venesection. CPTTM vacutainers were centrifuged at 1500 g for 15 min at room temperature and the peripheral blood mononuclear cell (PBMC) layer extracted, washed twice in 2 mls of phosphate-buffered saline (PBS) before being resuspended in freezing media (foetal bovine serum (Gibco, Thermo Fisher Scientific, Paisley, UK) with 10% dimethyl sulfoxide (DMSO, Merck Life Sciences, Gillingham, Dorset, UK)) frozen to −80 °C using isopropyl alcohol (Mr FrostyTM, Thermo Fisher Scientific, Paisley, UK), and transferred to liquid nitrogen within 48 h for long term storage.
Samples were analysed in batches. Frozen PBMCs were defrosted by resuspension in RPMI Glutamax medium (Gibco, Thermo Fisher Scientific, Paisley, UK) with 10% foetal bovine serum (FBS) (Thermo Fisher Scientific, Paisley, UK), washed once in media, counted (Countess 3 Automated cell counter, Thermo Fisher Scientific, Paisley, UK), and diluted to a concentration of 1 × 106/mL.
Cell types were chosen based on the existing literature and preliminary experiments [8]. (Supplemental Methods).

4.4. Antibiotic Stimulation

Patient PBMCs (1 × 106/mL) were plated into 96-well plates and incubated at 37 °C, 5% CO2 for 24 h (for monocyte analysis), or 72 h (for lymphocyte analysis) with or without antibiotics. Amoxicillin (Wockhardt, Wrexham, UK) and cefuroxime (Flynn Pharma, Stevenage, UK) were first resuspended in distilled water as per manufacturer’s instructions. Metronidazole (B. Braun Medical, Sheffield, UK), which came pre-dissolved, and the prepared amoxicillin and cefuroxime stocks were then diluted to working stock concentration in phosphate-buffered saline. Final concentrations of 5 µg/mL and 25 µg/mL for all antibiotics were chosen to represent lower and higher mean serum concentrations, respectively, based on data from pharmacokinetic data obtained in critically ill patients and patients undergoing major surgery [56,57,58,59].
To model the effect of antibiotics on PBMC response to a post-operative infection, patient PBMCs were additionally incubated with either heat-killed E. coli 0111:B4 (HKB, Thermo Fisher Scientific, Paisley, UK) at a concentration of 108/mL for 24 h (for monocyte analysis) or CD3/CD28 beads (Miltenyi Biotec, Woking, UK) at a concentration of 4:1 (beads: PBMCs) for 72 h (for lymphocyte analysis) with or without antibiotics. The dose of HKB and CD3/CD28 beads used for experiments in this study were ascertained in recent dose-finding experiments [8,60]. (Supplemental Methods).
Following incubation, plates were centrifuged at 400 g for 5 min at room temperature and the supernatant removed. To assess anergy in the in-depth lymphocyte characterisation panel, the plates were centrifuged as described every 24 h, and the supernatant removed and stored frozen for subsequent cytokine ELISA measurement and the cell pellet then resuspended in media with or without antibiotics as required.

4.5. Flow Cytometry

The cell surface markers and intracellular proteins analysed reflected pathways typically associated with sepsis and peri-operative immunosuppression [3,8,9,61]. To assess the effect of antibiotics on markers associated with monocyte phenotype, PBMCs were resuspended in cell staining buffer (Biolegend, London, UK) and incubated with fluorochrome-labelled antibodies to the following markers (CD14, CD16, HLA-DR, CD80, CD86, and CD274 (PD-L1)), viability stain (Aqua UV Live/Dead), and, after use of the Cytofix/perm fixation/permeabilization kit (Beckton Dickinson, Wokingham, UK) as per manufacturer recommendations, fluorochrome-labelled antibodies to the following intracellular cytokines (IL-1β, IL-6, IL-10, and TNF-α).
To assess the basic phenotype of lymphocytes, PBMCs were resuspended in cell staining buffer with fluorochrome-labelled antibodies to the following markers (CD3, CD4, CD8, CD19, CD25 (IL-2RA), CD28, CD127 (IL-7RA), CD152 (CTLA-4), and CD279 (PD-1)), viability stain (Aqua UV Live/Dead), and, after fixation/permeabilization, fluorochrome-labelled antibodies to the following intracellular cytokines (IL-2, IL-10, and IFN-γ). Details of products and concentrations used are listed in Supplemental Table S3.
Based on preliminary results, we performed a more focused and in-depth characterisation on T- lymphocytes. PBMCs were resuspended in cell staining buffer with fluorochrome-labelled antibodies to the following cell surface markers (CD3, CD4, CD8, CD19, CD25 (IL-2RA), CD28, CD95 (Fas), CD127 (IL-7RA), CD152 (CTLA-4), CD194 (CCR4), CD196 (CCR6), CD274 (PD-L1), CD279 (PD-1), HLA-DR), viability stain (Zombie near-infrared Live/Dead), and, after use of the Tru-nuclear fixation/permeabilization kit (Biolegend, London, UK) as per manufacturer recommendations, fluorochrome-labelled antibodies to the following intracellular cytokines (IL-2, IL-4, IL-10, IL-17A, and IFN-γ), proteins (NF-κB), and transcription factors (Fox-P3, STAT5, and T-bet). Details of products and concentrations used are listed in Supplemental Table S4.
For statistical analysis, lymphocyte differentiation was assessed using the following variables: CCR4, CCR6, IL-4, IL-17A, T-bet, STAT5 (all MFI), with Fox-P3 (MFI), Th1, Th2, Th17, and Treg (all % of parent population) for CD4+ lymphocytes, or Tc1, Tc2, and Tc17 (all % of parent population) for CD8+ lymphocytes. To assess Th1 subset phenotype, the following variables were included: CD28, Fas, IL-10, PD-1, IL-2R, IL-2, HLA-DR, IFN-γ, PD-L1, CTLA-4, IL-7R, NF-κB (all MFI), divided, and viability (both %).
Cells were acquired on an ID7000 spectral cell analyser (Sony Biotechnology Inc, Weybridge, UK) and analysed using ID7000 software (version 1.2, Sony Biotechnology Inc, Weybridge, UK). Alignment check beads (Sony Biotechnology Inc, Weybridge, UK) were used prior to running each experiment, and spectral references for each fluorochrome were added using either single stain labelled heat-killed cells (60 °C for 10 min, live/dead stain) or compensation beads (Beckton Dickinson, Wokingham, UK, all other markers) with appropriate negative controls. FMO (fluorescence minus one) samples were used to identify cell populations. The stopping gate was set at 10,000 events for either CD14++CD16− monocytes or CD4+ lymphocytes. An example gating strategy is shown in Supplementary Figure S10.

4.6. Cytokine ELISA

Supernatant IFN-γ and IL-10 were measured using Duoset ELISA kits (R&D Systems, Abingdon, UK) as per manufacturer instructions. Samples were diluted 1:2 in reagent dilutant. Optical densities were acquired on a SPECTROstar Nano microplate reader (BMG Labtech, Aylesbury, UK).

4.7. Statistics

Clinical and demographic data are presented either as median (inter-quartile range) or number (percentage). Flow cytometry data are presented as either median fluorescence intensity (MFI; arbitrary units), percentage positive cells, percentage of parent population, and compared using Friedmans test without post hoc correction or Wilcoxon test for multiple or paired analyses, respectively.
To identify statistically significant discriminators between two groups, we conducted multiple comparisons using a Mann–Whitney test and calculated a corrected p-value (−log10) with a False Discovery Rate of 5%, and data presented using a volcano plot. Time-to-event analysis was conducted using log-rank with a Gehan–Breslow–Wilcoxon test and presented as a Kaplan–Meier plot. Graphs were constructed, and statistical analysis performed using Prism (version 10, GraphPad, San Diego, CA, USA).

5. Conclusions

In summary the choice of antibiotics impacts immune function ex vivo following major surgery, with cefuroxime associated with immunomodulatory effects on CD4+ lymphocytes. The functional implications on the development of subsequent post-operative infectious complications and long-term cancer-free survival require further investigation.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/antibiotics14101026/s1, Supplementary Methods, Supplementary Tables S1–S4: Table S1: Summary of global antimicrobial prophylaxis use; Table S2: Clinical characteristics of whole patient cohort; Table S3: Flow cytometry fluorochrome panels; Table S4: Lymphocyte in-depth flow cytometry fluorochrome panel; and Supplementary Figures S1–S14: Figure S1: Consort diagram of recruited patients; Figure S2: Effect of amoxicillin and metronidazole on monocyte and lymphocyte immunophenotype; Figure S3: Summary of effects of cefuroxime on CD4+ lymphocyte immunophenotype; Figure S4: Effect of cefuroxime and combined cefuroxime-metronidazole on monocyte and lymphocyte immunophenotype; Figure S5: Cefuroxime has immunomodulatory effects on lymphocyte differentiation; Figure S6: Cefuroxime has immunomodulatory effects on Th1 lymphocyte immunophenotype; Figure S7: Cefuroxime has an immunomodulatory effect on cytokine release; Figure S8: Effect of stimulus on monocyte and lymphocyte immunophenotype; Figure S9: The immunomodulatory effects of cefuroxime may not be clinically relevant; Figure S10: Example gating strategy to identify classical monocytes and CD4+ and CD8+ lymphocytes; Figure S11: Example gating strategy to identify granulocytes and classical monocytes; Figure S12: Effect of antibiotics on stimulated volunteer granulocyte function; Figure S13: Effect of antibiotics on stimulated volunteer monocyte function; Figure S14: Time-course of effect of stimulus on monocyte HLA-DR expression and CD4+ lymphocyte viability.

Author Contributions

Study design: T.A.C.S., D.B., and N.A.; Patient recruitment and sample collection: University College London Hospitals Critical Care Research Team. Sample processing: T.A.C.S., N.A., and University College London Hospitals Critical Care Research Team; Experimental acquisition: T.A.C.S., W.P., R.H., and R.L.; Clinical data collection: S.P., J.W. (Jack Williams), A.V.W., and T.A.C.S.; Statistical analysis: T.A.C.S., J.W. (Jack Williams), W.P., and N.A.; Critical Review: M.S., J.W. (John Whittle), and R.M. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by RCoA/BJA Project Award 2022 (TS—WKR0-2022-0020), Intensive Care Society New Investigator Award 2022 (TS), European Society of Intensive Care Medicine (ESICM) New Investigator Award 2018 (NA), and University College London Precision AMR grant 2020 (NA, TS, MS). NA acknowledges salary support from UK Medical Research Council (MR/W030489/1). DB and RM acknowledge salary support from NIHR UCLH Biomedical Research Centre.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki, and approved by the London—Queen Square Research Ethics Committee (REC reference 20/LO/1024) on 20 October 2020.

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

The raw data supporting the conclusions of this article will be made available by the authors on request without undue restriction.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. The International Surgical Outcomes Study Group. Global patient outcomes after elective surgery: Prospective cohort study in 27 low-, middle- and high-income countries. Br. J. Anaesth. 2017, 119, 553. [Google Scholar] [CrossRef]
  2. Moonesinghe, S.R.; Harris, S.; Mythen, M.G.; Rowan, K.M.; Haddad, F.S.; Emberton, M.; Grocott, M.P. Survival after postoperative morbidity: A longitudinal observational cohort study. Br. J. Anaesth. 2014, 113, 977–984. [Google Scholar] [CrossRef] [PubMed]
  3. Desborough, J.P. The stress response to trauma and surgery. Br. J. Anaesth. 2000, 85, 109–117. [Google Scholar] [CrossRef]
  4. Albertsmeier, M.; Prix, N.J.; Winter, H.; Bazhin, A.; Werner, J.; Angele, M.K. Monocyte-Dependent Suppression of T-Cell Function in Postoperative Patients and Abdominal Sepsis. Shock 2017, 48, 651–656. [Google Scholar] [CrossRef]
  5. Cheron, A.; Floccard, B.; Allaouchiche, B.; Guignant, C.; Poitevin, F.; Malcus, C.; Crozon, J.; Faure, A.; Guillaume, C.; Marcotte, G.; et al. Lack of recovery in monocyte human leukocyte antigen-DR expression is independently associated with the development of sepsis after major trauma. Crit. Care 2010, 14, R208. [Google Scholar] [CrossRef] [PubMed]
  6. Torrance, H.D.; Zhang, P.; Longbottom, E.R.; Mi, Y.; Whalley, J.P.; Allcock, A.; Kwok, A.J.; Cano-Gamez, E.; Geoghegan, C.G.; Burnham, K.L.; et al. A Transcriptomic Approach to Understand Patient Susceptibility to Pneumonia After Abdominal Surgery. Ann. Surg. 2023, 279, 510–520. [Google Scholar] [CrossRef] [PubMed]
  7. Lukaszewski, R.A.; Jones, H.E.; Gersuk, V.H.; Russell, P.; Simpson, A.; Brealey, D.; Walker, J.; Thomas, M.; Whitehouse, T.; Ostermann, M.; et al. Presymptomatic diagnosis of postoperative infection and sepsis using gene expression signatures. Intensive Care Med. 2022, 48, 1133–1143. [Google Scholar] [CrossRef]
  8. Snow, T.A.C.; Waller, A.V.; Loye, R.; Ryckaert, F.; Cesar, A.; Saleem, N.; Roy, R.; Whittle, J.; Al-Hindawi, A.; Das, A.; et al. Early dynamic changes to monocytes following major surgery are associated with subsequent infections. Front. Immunol. 2024, 15, 1352556. [Google Scholar] [CrossRef]
  9. Boomer, J.S.; To, K.; Chang, K.C.; Takasu, O.; Osborne, D.F.; Walton, A.H.; Bricker, T.L.; Jarman, S.D., 2nd; Kreisel, D.; Krupnick, A.S.; et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 2011, 306, 2594–2605. [Google Scholar] [CrossRef]
  10. de Jonge, S.W.; Boldingh, Q.J.J.; Solomkin, J.S.; Dellinger, E.P.; Egger, M.; Salanti, G.; Allegranzi, B.; Boermeester, M.A. Effect of postoperative continuation of antibiotic prophylaxis on the incidence of surgical site infection: A systematic review and meta-analysis. Lancet Infect. Dis. 2020, 20, 1182–1192. [Google Scholar] [CrossRef]
  11. National Institute for Health and Care Excellence (NICE). Surgical Site Infections: Prevention and Treatment: NG125; NICE: Manchester, UK, 2020. [Google Scholar]
  12. Fowler, A.J.; Dias, P.; Hui, S.; Cashmore, R.; Laloo, R.; Ahmad, A.N.; Gillies, M.A.; Wan, Y.I.; Pearse, R.M.; Abbott, T.E.F. Liberal or restrictive antimicrobial prophylaxis for surgical site infection: Systematic review and meta-analysis of randomised trials. Br. J. Anaesth. 2022, 129, 104–113. [Google Scholar] [CrossRef]
  13. British National Formulary (BNF). Antibacterials, Use for Prophylaxis. 2024. Available online: https://bnfc.nice.org.uk/treatment-summaries/antibacterials-use-for-prophylaxis/ (accessed on 1 October 2025).
  14. Stavropoulou, E.; Atkinson, A.; Eisenring, M.C.; Fux, C.A.; Marschall, J.; Senn, L.; Troillet, N. Association of antimicrobial perioperative prophylaxis with cefuroxime plus metronidazole or amoxicillin/clavulanic acid and surgical site infections in colorectal surgery. Antimicrob. Resist. Infect. Control 2023, 12, 105. [Google Scholar] [CrossRef]
  15. Snow, T.A.C.; Singer, M.; Arulkumaran, N. Antibiotic-Induced Immunosuppression-A Focus on Cellular Immunity. Antibiotics 2024, 13, 1034. [Google Scholar] [CrossRef]
  16. Barath, B.; Jasz, D.K.; Horvath, T.; Barath, B.; Maroti, G.; Strifler, G.; Varga, G.; Sandor, L.; Perenyi, D.; Tallosy, S.; et al. Mitochondrial Side Effects of Surgical Prophylactic Antibiotics Ceftriaxone and Rifaximin Lead to Bowel Mucosal Damage. Int. J. Mol. Sci. 2022, 23, 5064. [Google Scholar] [CrossRef]
  17. Wakefield, C.H.; Carey, P.D.; Foulds, S.; Monson, J.R.; Guillou, P.J. Changes in major histocompatibility complex class II expression in monocytes and T cells of patients developing infection after surgery. Br. J. Surg. 1993, 80, 205–209. [Google Scholar] [CrossRef] [PubMed]
  18. Dietz, A.; Heimlich, F.; Daniel, V.; Polarz, H.; Weidauer, H.; Maier, H. Immunomodulating effects of surgical intervention in tumors of the head and neck. Otolaryngol. Head. Neck Surg. 2000, 123, 132–139. [Google Scholar] [CrossRef]
  19. Delogu, G.; Moretti, S.; Antonucci, A.; Marcellini, S.; Masciangelo, R.; Famularo, G.; Signore, L.; De Simone, C. Apoptosis and surgical trauma: Dysregulated expression of death and survival factors on peripheral lymphocytes. Arch. Surg. 2000, 135, 1141–1147. [Google Scholar] [CrossRef] [PubMed]
  20. Edwards, M.R.; Sultan, P.; del Arroyo, A.G.; Whittle, J.; Karmali, S.N.; Moonesinghe, S.R.; Haddad, F.S.; Mythen, M.G.; Singer, M.; Ackland, G.L. Metabolic dysfunction in lymphocytes promotes postoperative morbidity. Clin. Sci. 2015, 129, 423–437. [Google Scholar] [CrossRef]
  21. Zhou, C.; Wang, Z.; Jiang, B.; Di, J.; Su, X. Monitoring Pre- and Post-Operative Immune Alterations in Patients With Locoregional Colorectal Cancer Who Underwent Laparoscopy by Single-Cell Mass Cytometry. Front. Immunol. 2022, 13, 807539. [Google Scholar] [CrossRef] [PubMed]
  22. Kruse, B.; Buzzai, A.C.; Shridhar, N.; Braun, A.D.; Gellert, S.; Knauth, K.; Pozniak, J.; Peters, J.; Dittmann, P.; Mengoni, M.; et al. CD4+ T cell-induced inflammatory cell death controls immune-evasive tumours. Nature 2023, 618, 1033–1040. [Google Scholar] [CrossRef]
  23. Sulzgruber, P.; Thaler, B.; Koller, L.; Baumgartner, J.; Pilz, A.; Steininger, M.; Schnaubelt, S.; Fleck, T.; Laufer, G.; Steinlechner, B.; et al. CD4+CD28 (null) T Lymphocytes are Associated with the Development of Atrial Fibrillation after Elective Cardiac Surgery. Sci. Rep. 2018, 8, 9624. [Google Scholar] [CrossRef]
  24. Ross, S.H.; Cantrell, D.A. Signaling and Function of Interleukin-2 in T Lymphocytes. Annu. Rev. Immunol. 2018, 36, 411–433. [Google Scholar] [CrossRef]
  25. White, M.; Mahon, V.; Grealy, R.; Doherty, D.G.; Stordeur, P.; Kelleher, D.P.; McManus, R.; Ryan, T. Post-operative infection and sepsis in humans is associated with deficient gene expression of gammac cytokines and their apoptosis mediators. Crit. Care 2011, 15, R158. [Google Scholar] [CrossRef]
  26. Li, H.; Xiong, S.T.; Zhang, S.X.; Liu, S.B.; Luo, Y. Effects of surgical trauma on interleukin 2 production and interleukin 2 receptor expression. J. Tongji Med. Univ. 1992, 12, 160–163. [Google Scholar] [CrossRef] [PubMed]
  27. Berguer, R.; Bravo, N.; Bowyer, M.; Egan, C.; Knolmayer, T.; Ferrick, D. Major surgery suppresses maximal production of helper T-cell type 1 cytokines without potentiating the release of helper T-cell type 2 cytokines. Arch. Surg. 1999, 134, 540–544. [Google Scholar] [CrossRef] [PubMed]
  28. Nichols, P.H.; Ramsden, C.W.; Ward, U.; Sedman, P.C.; Primrose, J.N. Perioperative immunotherapy with recombinant interleukin 2 in patients undergoing surgery for colorectal cancer. Cancer Res. 1992, 52, 5765–5769. [Google Scholar]
  29. Manzella, J.P.; Clark, J.K. Effects of moxalactam and cefuroxime on mitogen-stimulated human mononuclear leukocytes. Antimicrob. Agents Chemother. 1983, 23, 360–363. [Google Scholar] [CrossRef]
  30. Clot, J.; Pelous, C.; Carriere, V.; Dessaint, J.P. Effect of cephalosporins on lymphocyte proliferation and immunoglobulin E production. Pathol. Biol. 1987, 35, 1457–1460. [Google Scholar] [PubMed]
  31. Villa, M.L.; Armelloni, S.; Ferrario, E.; Ottaviani, F.; Clerici, M. Interference of cephalosporins with immune response: Effects of cefonicid on human T-helper cells. Int. J. Immunopharmacol. 1991, 13, 1099–1107. [Google Scholar] [CrossRef]
  32. Zyzynska-Granica, B.; Trzaskowski, B.; Dutkiewicz, M.; Zegrocka-Stendel, O.; Machcinska, M.; Bocian, K.; Kowalewska, M.; Koziak, K. The anti-inflammatory potential of cefazolin as common gamma chain cytokine inhibitor. Sci. Rep. 2020, 10, 2886. [Google Scholar] [CrossRef]
  33. Mor, F.; Cohen, I.R. Beta-lactam antibiotics modulate T-cell functions and gene expression via covalent binding to cellular albumin. Proc. Natl. Acad. Sci. USA 2013, 110, 2981–2986. [Google Scholar] [CrossRef] [PubMed]
  34. Refaeli, Y.; Van Parijs, L.; London, C.A.; Tschopp, J.; Abbas, A.K. Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity 1998, 8, 615–623. [Google Scholar] [CrossRef]
  35. Hieronymus, T.; Blank, N.; Gruenke, M.; Winkler, S.; Haas, J.P.; Kalden, J.R.; Lorenz, H.M. CD 95-independent mechanisms of IL-2 deprivation-induced apoptosis in activated human lymphocytes. Cell Death Differ. 2000, 7, 538–547. [Google Scholar] [CrossRef]
  36. Chen, D.; Falsetti, S.C.; Frezza, M.; Milacic, V.; Kazi, A.; Cui, Q.C.; Long, T.E.; Turos, E.; Dou, Q.P. Anti-tumor activity of N-thiolated beta-lactam antibiotics. Cancer Lett. 2008, 268, 63–69. [Google Scholar] [CrossRef]
  37. Smith, D.M.; Kazi, A.; Smith, L.; Long, T.E.; Heldreth, B.; Turos, E.; Dou, Q.P. A novel beta-lactam antibiotic activates tumor cell apoptotic program by inducing DNA damage. Mol. Pharmacol. 2002, 61, 1348–1358. [Google Scholar] [CrossRef]
  38. Yoshioka, D.; Kajiwara, C.; Ishii, Y.; Umeki, K.; Hiramatsu, K.; Kadota, J.; Tateda, K. Efficacy of beta-Lactam-plus-Macrolide Combination Therapy in a Mouse Model of Lethal Pneumococcal Pneumonia. Antimicrob. Agents Chemother. 2016, 60, 6146–6154. [Google Scholar] [CrossRef]
  39. Cheng, R.Y.; Li, M.; Li, S.S.; He, M.; Yu, X.H.; Shi, L.; He, F. Vancomycin and ceftriaxone can damage intestinal microbiota and affect the development of the intestinal tract and immune system to different degrees in neonatal mice. Pathog. Dis. 2017, 75, ftx104. [Google Scholar] [CrossRef] [PubMed]
  40. Gao, Y.L.; Yao, Y.; Zhang, X.; Chen, F.; Meng, X.L.; Chen, X.S.; Wang, C.L.; Liu, Y.C.; Tian, X.; Shou, S.T.; et al. Regulatory T Cells: Angels or Demons in the Pathophysiology of Sepsis? Front. Immunol. 2022, 13, 829210. [Google Scholar] [CrossRef] [PubMed]
  41. Saito, Y.; Shimada, M.; Utsunomiya, T.; Morine, Y.; Imura, S.; Ikemoto, T.; Mori, H.; Hanaoka, J.; Iwahashi, S.; Yamada, S.; et al. Regulatory T cells in the blood: A new marker of surgical stress. Surg. Today 2013, 43, 608–612. [Google Scholar] [CrossRef]
  42. Tang, F.; Tie, Y.; Tu, C.; Wei, X. Surgical trauma-induced immunosuppression in cancer: Recent advances and the potential therapies. Clin. Transl. Med. 2020, 10, 199–223. [Google Scholar] [CrossRef]
  43. Jiang, Y.; Gao, S.; Sun, H.; Wu, X.; Gu, J.; Wu, H.; Liao, Y.; Ben-Ami, R.; Miao, C.; Shen, R.; et al. Targeting NEDD8 suppresses surgical stress-facilitated metastasis of colon cancer via restraining regulatory T cells. Cell Death Dis. 2024, 15, 8. [Google Scholar] [CrossRef]
  44. Natusch, L.; Heiduk, M.; Klimova, A.; Beer, C.; Willms, T.; Digomann, D.; Reiche, C.; Aust, D.E.; Hempel, S.; Oehme, F.; et al. The Value of Blood T Cell Frequencies for Risk Prediction of Postoperative Complications in Pancreatic Cancer Surgery. Ann. Surg. Open 2025, 6, e545. [Google Scholar] [CrossRef]
  45. Scholz, A.S.; Handke, J.; Gillmann, H.J.; Zhang, Q.; Dehne, S.; Janssen, H.; Arens, C.; Espeter, F.; Sander, A.; Giannitsis, E.; et al. Frontline Science: Low regulatory T cells predict perioperative major adverse cardiovascular and cerebrovascular events after noncardiac surgery. J. Leukoc. Biol. 2020, 107, 717–730. [Google Scholar] [CrossRef]
  46. Ivashkiv, L.B. IFNgamma: Signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy. Nat. Rev. Immunol. 2018, 18, 545–558. [Google Scholar] [CrossRef] [PubMed]
  47. Longbottom, E.R.; Torrance, H.D.; Owen, H.C.; Fragkou, P.C.; Hinds, C.J.; Pearse, R.M.; O’Dwyer, M.J. Features of Postoperative Immune Suppression Are Reversible With Interferon Gamma and Independent of Interleukin-6 Pathways. Ann. Surg. 2016, 264, 370–377. [Google Scholar] [CrossRef]
  48. Rentenaar, R.J.; de Metz, J.; Bunders, M.; Wertheim-van Dillen, P.M.; Gouma, D.J.; Romijn, J.A.; Sauerwein, H.P.; ten Berge, I.J.; van Lier, R.A. Interferon-gamma administration after abdominal surgery rescues antigen-specific helper T cell immune reactivity. Clin. Exp. Immunol. 2001, 125, 401–408. [Google Scholar] [CrossRef] [PubMed]
  49. Sacha, P.T.; Zaremba, M.L.; Jakoniuk, P. The effect of selected antibacterial antibiotics on production of interferon gamma (IFN-G) by mouse T lymphocytes stimulated by Listeria monocytogenes. Med. Dosw. Mikrobiol. 1999, 51, 413–419. [Google Scholar] [PubMed]
  50. Neftel, K.A.; Muller, M.R.; Widmer, U.; Hugin, A.W. Beta-lactam antibiotics inhibit human in vitro granulopoiesis and proliferation of some other cell types. Cell Biol. Toxicol. 1986, 2, 513–521. [Google Scholar] [CrossRef]
  51. Hertl, M.; Geisel, J.; Boecker, C.; Merk, H.F. Selective generation of CD8+ T-cell clones from the peripheral blood of patients with cutaneous reactions to beta-lactam antibiotics. Br. J. Dermatol. 1993, 128, 619–626. [Google Scholar] [CrossRef]
  52. Yang, L.; Cai, Y.; Fu, X. Impact of Perioperative Multiple Doses of Glucocorticoids on Peripheral Blood Lymphocyte Subsets and Inflammatory Cytokines in Patients With Non-small Cell Lung Cancer. Front. Surg. 2022, 9, 859984. [Google Scholar] [CrossRef]
  53. Martin, D.; Mantziari, S.; Demartines, N.; Hubner, M.; Group, E.S.A.S. Defining Major Surgery: A Delphi Consensus Among European Surgical Association (ESA) Members. World J. Surg. 2020, 44, 2211–2219. [Google Scholar] [CrossRef]
  54. Protopapa, K.L.; Simpson, J.C.; Smith, N.C.; Moonesinghe, S.R. Development and validation of the Surgical Outcome Risk Tool (SORT). Br. J. Surg. 2014, 101, 1774–1783. [Google Scholar] [CrossRef]
  55. Barnes, J.; Hunter, J.; Harris, S.; Shankar-Hari, M.; Diouf, E.; Jammer, I.; Kalkman, C.; Klein, A.A.; Corcoran, T.; Dieleman, S.; et al. Systematic review and consensus definitions for the Standardised Endpoints in Perioperative Medicine (StEP) initiative: Infection and sepsis. Br. J. Anaesth. 2019, 122, 500–508. [Google Scholar] [CrossRef]
  56. Marti, C.; Stirnemann, J.; Lescuyer, P.; Tonoli, D.; von Dach, E.; Group, O.T.S.; Huttner, A. Therapeutic drug monitoring and clinical outcomes in severely ill patients receiving amoxicillin: A single-centre prospective cohort study. Int. J. Antimicrob. Agents 2022, 59, 106601. [Google Scholar] [CrossRef] [PubMed]
  57. Carlier, M.; Noe, M.; Roberts, J.A.; Stove, V.; Verstraete, A.G.; Lipman, J.; De Waele, J.J. Population pharmacokinetics and dosing simulations of cefuroxime in critically ill patients: Non-standard dosing approaches are required to achieve therapeutic exposures. J. Antimicrob. Chemother. 2014, 69, 2797–2803. [Google Scholar] [CrossRef] [PubMed]
  58. Frasca, D.; Dahyot-Fizelier, C.; Adier, C.; Mimoz, O.; Debaene, B.; Couet, W.; Marchand, S. Metronidazole and hydroxymetronidazole central nervous system distribution: 2. cerebrospinal fluid concentration measurements in patients with external ventricular drain. Antimicrob. Agents Chemother. 2014, 58, 1024–1027. [Google Scholar] [CrossRef]
  59. Lonsdale, D.O.; Kipper, K.; Baker, E.H.; Barker, C.I.S.; Oldfield, I.; Philips, B.J.; Johnston, A.; Rhodes, A.; Sharland, M.; Standing, J.F. beta-Lactam antimicrobial pharmacokinetics and target attainment in critically ill patients aged 1 day to 90 years: The ABDose study. J. Antimicrob. Chemother. 2020, 75, 3625–3634. [Google Scholar] [CrossRef]
  60. Walsh, R.; Snow, T.A.C.; Martinez, A.Z.; Brealey, D.; Singer, M.; Das, A.; Arulkumaran, N. The amphiregulin- epidermal growth factor receptor axis as a therapeutic target in sepsis. Front. Immunol. 2025, 16, 1638244. [Google Scholar] [CrossRef] [PubMed]
  61. Boomer, J.S.; Shuherk-Shaffer, J.; Hotchkiss, R.S.; Green, J.M. A prospective analysis of lymphocyte phenotype and function over the course of acute sepsis. Crit. Care 2012, 16, R112. [Google Scholar] [CrossRef]
Antibiotics 14 01026 g001
Figure 1. Effect of cefuroxime on lymphocyte immunophenotype. PBMCs isolated from patients immediately post-operatively (n = 12) were incubated for 72 h alone or with low (5 μg/mL, (a.i.), light orange) or high (25 μg/mL, (a.ii.), dark orange) doses of cefuroxime and the effect on CD4+ lymphocyte immunophenotype assessed. Data expressed as volcano plots generated by calculating a corrected q-value (−log10) using a False Discovery Rate (FDR) of 5% using the two-stage step-up method of Benjamini, Krieger, and Yekutieli. Red area represents markers upregulated by cefuroxime compared to control, blue area those markers downregulated. A dose-dependent effect was seen on IL-2 concentration (b.i.,b.iii.), IL-2R expression (b.ii.,b.iii.), viability (c.i.), and IFN-γ concentration (c.ii.,c.iii.). Data expressed as box and whisker plots normalised to control; dot represents the individual patient, horizontal line the median, box the interquartile range, and whisker the range, compared using Friedmans test (only p < 0.05 show) or as contour plots, where numbers represent percentage.
Figure 1. Effect of cefuroxime on lymphocyte immunophenotype. PBMCs isolated from patients immediately post-operatively (n = 12) were incubated for 72 h alone or with low (5 μg/mL, (a.i.), light orange) or high (25 μg/mL, (a.ii.), dark orange) doses of cefuroxime and the effect on CD4+ lymphocyte immunophenotype assessed. Data expressed as volcano plots generated by calculating a corrected q-value (−log10) using a False Discovery Rate (FDR) of 5% using the two-stage step-up method of Benjamini, Krieger, and Yekutieli. Red area represents markers upregulated by cefuroxime compared to control, blue area those markers downregulated. A dose-dependent effect was seen on IL-2 concentration (b.i.,b.iii.), IL-2R expression (b.ii.,b.iii.), viability (c.i.), and IFN-γ concentration (c.ii.,c.iii.). Data expressed as box and whisker plots normalised to control; dot represents the individual patient, horizontal line the median, box the interquartile range, and whisker the range, compared using Friedmans test (only p < 0.05 show) or as contour plots, where numbers represent percentage.
Antibiotics 14 01026 g001
Antibiotics 14 01026 g002
Figure 2. Effect of cefuroxime on CD4+ lymphocyte differentiation. PBMCs isolated from patients immediately post-operatively (n = 16) were incubated for 72 h alone or with low (5 μg/mL, (a.i.), light orange) or high (25 μg/mL, (a.ii.), dark orange) doses of cefuroxime and the effect on CD4+ lymphocyte differentiation (a.,b.) was assessed. Data expressed as volcano plots generated by calculating a corrected q-value (−log10) using a False Discovery Rate (FDR) of 5% using the two-stage step-up method of Benjamini, Krieger, and Yekutieli. Red area represents markers upregulated by cefuroxime compared to control, and blue area those markers downregulated. A dose-dependent effect was seen on the Th1 population differentiation (b.i.). Data expressed as box and whisker plots normalised to control, dot represents the individual patient, horizontal line the median, box the interquartile range, and whisker the range, compared using Friedmans test (only p < 0.05 show) or as contour plots, where numbers represent percentage (b.ii.).
Figure 2. Effect of cefuroxime on CD4+ lymphocyte differentiation. PBMCs isolated from patients immediately post-operatively (n = 16) were incubated for 72 h alone or with low (5 μg/mL, (a.i.), light orange) or high (25 μg/mL, (a.ii.), dark orange) doses of cefuroxime and the effect on CD4+ lymphocyte differentiation (a.,b.) was assessed. Data expressed as volcano plots generated by calculating a corrected q-value (−log10) using a False Discovery Rate (FDR) of 5% using the two-stage step-up method of Benjamini, Krieger, and Yekutieli. Red area represents markers upregulated by cefuroxime compared to control, and blue area those markers downregulated. A dose-dependent effect was seen on the Th1 population differentiation (b.i.). Data expressed as box and whisker plots normalised to control, dot represents the individual patient, horizontal line the median, box the interquartile range, and whisker the range, compared using Friedmans test (only p < 0.05 show) or as contour plots, where numbers represent percentage (b.ii.).
Antibiotics 14 01026 g002
Antibiotics 14 01026 g003
Figure 3. Effect of cefuroxime on Th1 lymphocyte immunophenotype. PBMCs isolated from patients immediately post-operatively (n = 16) were incubated for 72 h alone or with low (5 μg/mL, (a.i.), light orange) or high (25 μg/mL, (a.ii.), dark orange) doses of cefuroxime and the effect on Th1 lymphocyte immunophenotype (a.,b.) assessed. Data expressed as volcano plots generated by calculating a corrected q-value (−log10) using a False Discovery Rate (FDR) of 5% using the two-stage step-up method of Benjamini, Krieger and Yekutieli. Red area represents markers upregulated by cefuroxime compared to control, blue area those markers downregulated. A dose-dependent effect was seen on the Th1 population Fas receptor expression (b.i.) and viability (b.ii.). Data expressed as box and whisker plots normalised to control, dot represents the individual patient, horizontal line the median, box the interquartile range, and whisker the range, compared using Friedmans test (only p < 0.05 show) or as contour plots, where numbers represent percentage (b.iii.).
Figure 3. Effect of cefuroxime on Th1 lymphocyte immunophenotype. PBMCs isolated from patients immediately post-operatively (n = 16) were incubated for 72 h alone or with low (5 μg/mL, (a.i.), light orange) or high (25 μg/mL, (a.ii.), dark orange) doses of cefuroxime and the effect on Th1 lymphocyte immunophenotype (a.,b.) assessed. Data expressed as volcano plots generated by calculating a corrected q-value (−log10) using a False Discovery Rate (FDR) of 5% using the two-stage step-up method of Benjamini, Krieger and Yekutieli. Red area represents markers upregulated by cefuroxime compared to control, blue area those markers downregulated. A dose-dependent effect was seen on the Th1 population Fas receptor expression (b.i.) and viability (b.ii.). Data expressed as box and whisker plots normalised to control, dot represents the individual patient, horizontal line the median, box the interquartile range, and whisker the range, compared using Friedmans test (only p < 0.05 show) or as contour plots, where numbers represent percentage (b.iii.).
Antibiotics 14 01026 g003
Table 1. Clinical characteristics of antibiotic characterisation cohort.
Table 1. Clinical characteristics of antibiotic characterisation cohort.
VariableAntibiotic Characterisation Cohort (n = 28)Immunophenotyping Cohort (n = 12)Lymphocyte Characterisation Cohort (n = 16)
Age (years)64 (54–75)61 (50–70)64 (57–77)
Biological Sex (% male) 15 (54%)8 (67%)7 (44%)
BMI 25 (21–30)24 (21–27)26 (22–32)
Co-morbidities
Hypertension (%) 13 (46%)7 (58%)6 (38%)
Cardiovascular disease (%) 5 (18%)3 (25%)2 (13%)
Respiratory disease (%)6 (21%)3 (25%)3 (19%)
Type 2 diabetes (%) 6 (21%)4 (33%)2 (13%)
ASA Grade (%) 3 (3–3)3 (3–3)3 (3–3)
Active cancer (%) 27 (96%)12 (100%)15 (94%)
Cancer staging 2 (2–3)2 (2–2)2 (2–2)
Neoadjuvant chemotherapy (%) 17 (61%)8 (67%)9 (56%)
SORT Score (%) 1.48 (0.0–2.1)1.5 (1.4–3.2)1.1 (0.7–1.6%)
Type of surgery
Upper GI (%) 16 (57%)9 (75%)7 (44%)
Lower GI (%) 2 (7%)0%2 (13%)
Maxillofacial (%) 5 (18%)2 (17%)2 (13%)
Gynaecological (%) 5 (18%)1 (8%)4 (25%)
Peri-operative antibiotics
Prophylaxis administered (%) 28 (100%)12 (100%)16 (100%)
Duration of prophylaxis (days) 1 (1–1)1 (1–1)1 (1–1)
Cefuroxime and metronidazole 17 (61%)9 (75%)8 (50%)
Co-amoxiclav 5 (18%)2 (17%)3 (19%)
Co-amoxiclav and gentamicin 1 (4%)0%1 (6%)
Co-amoxiclav and teicoplanin 1 (4%)0%1 (6%)
Ciprofloxacin and clindamycin 2 (7%)1 (8%)1 (6%)
Ciprofloxacin and metronidazole 1 (4%)0%1 (6%)
Gentamicin 1 (4%)0%1 (6%)
Intra-operative dexamethasone use (%) 23 (82%)11 (92%)12 (75%)
Operation duration (mins) 302 (220–409)247 (211–380)328 (252–446)
Blood loss (mls) 300 (200–600)200 (200–625)300 (200–525)
Peri-operative blood transfusion (%) 2 (7%)1 (8%)3 (19%)
Post-op infection 11 (39%)4 (33%)7 (44%)
Chest 7 (25%)2 (17%)5 (31%)
Wound 3 (11%)2 (17%)1 (6%)
Other/Unclear 2 (7%)0%2 (13%)
Clavien–Dindo classification 2 (1–2)2 (2–2)2 (1–2)
Hospital length of stay (days) 12 (8–20)10 (8–13)13 (8–23)
In-hospital death (%) 2 (7%)2 (9%)0%
Abbreviations: ASA: American association of anaesthesiologists, GI: gastrointestinal.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Paketci, S.; Williams, J.; Pisciotta, W.; Loye, R.; Waller, A.V.; Haque, R.; Brealey, D.; Singer, M.; Whittle, J.; Moonesinghe, R.; et al. Peri-Operative Antimicrobial Prophylaxis Modulates CD4+ Lymphocyte Immunophenotype Ex Vivo in High-Risk Patients Undergoing Major Elective Surgery—A Preliminary Observational Study. Antibiotics 2025, 14, 1026. https://doi.org/10.3390/antibiotics14101026

AMA Style

Paketci S, Williams J, Pisciotta W, Loye R, Waller AV, Haque R, Brealey D, Singer M, Whittle J, Moonesinghe R, et al. Peri-Operative Antimicrobial Prophylaxis Modulates CD4+ Lymphocyte Immunophenotype Ex Vivo in High-Risk Patients Undergoing Major Elective Surgery—A Preliminary Observational Study. Antibiotics. 2025; 14(10):1026. https://doi.org/10.3390/antibiotics14101026

Chicago/Turabian Style

Paketci, Susi, Jack Williams, Walter Pisciotta, Richard Loye, Alessia V. Waller, Rahila Haque, David Brealey, Mervyn Singer, John Whittle, Ramani Moonesinghe, and et al. 2025. "Peri-Operative Antimicrobial Prophylaxis Modulates CD4+ Lymphocyte Immunophenotype Ex Vivo in High-Risk Patients Undergoing Major Elective Surgery—A Preliminary Observational Study" Antibiotics 14, no. 10: 1026. https://doi.org/10.3390/antibiotics14101026

APA Style

Paketci, S., Williams, J., Pisciotta, W., Loye, R., Waller, A. V., Haque, R., Brealey, D., Singer, M., Whittle, J., Moonesinghe, R., Arulkumaran, N., Snow, T. A. C., & the University College London Hospitals Critical Care Research Team. (2025). Peri-Operative Antimicrobial Prophylaxis Modulates CD4+ Lymphocyte Immunophenotype Ex Vivo in High-Risk Patients Undergoing Major Elective Surgery—A Preliminary Observational Study. Antibiotics, 14(10), 1026. https://doi.org/10.3390/antibiotics14101026

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop